Synlogic, Inc. (SYBX): Shareholders' Equity
$11.86M
As of 2025-12-31
$12.02M
As of 2026-06-30
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $11.86M | -7.0% | 2026-03-12, Balance as of period end |
| 2024-12-31 | $12.75M | -61.1% | 2026-03-12, Balance as of period end |
| 2023-12-31 | $32.77M | n/c | 2025-03-06, Balance as of period end |
| 2022-12-31 | $82.61M | -43.9% | 2024-03-19, Balance as of period end |
| 2021-12-31 | $147.27M | +27.9% | 2023-03-29, Balance as of period end |
| 2020-12-31 | $115.14M | -26.6% | 2022-03-17, Balance as of period end |
| 2019-12-31 | $156.91M | +26.4% | 2021-03-25, Balance as of period end |
| 2018-12-31 | $124.10M | +45.9% | 2020-03-12, Balance as of period end |
| 2017-12-31 | $85.04M | +900.1% | 2019-03-12, Balance as of period end |
| 2016-12-31 | $8.50M | -90.0% | 2018-03-20, Balance as of period end |
| 2015-12-31 | $85.02M | n/m | 2017-03-15, Balance as of period end |
| 2014-12-31 | -$47.95M | n/m | 2017-03-15, Balance as of period end |
| 2013-12-31 | -$29.91M | n/a | 2016-03-30, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| Synlogic, Inc. (SYBX) | 2025-12-31 | $11.86M | -7.0% |
| Abbott Laboratories (ABT) | 2025-12-31 | $52.13B | +9.4% |
| Bristol Myers Squibb Co (BMY) | 2025-12-31 | $18.47B | +13.1% |
| TherapeuticsMD, Inc. (TXMD) | 2025-12-31 | $26.88M | -1.8% |
| Eli Lilly & Co (LLY) | 2025-12-31 | $26.54B | +85.9% |
| Pfizer Inc (PFE) | 2025-12-31 | $86.78B | -1.9% |
| Johnson & Johnson (JNJ) | 2025-12-28 | $81.54B | +14.1% |
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $161.55M | +0.3% |
| Merck & Co., Inc. (MRK) | 2025-12-31 | $52.66B | +13.6% |
Compare SYBX, ABT, BMY, TXMD side by side · Screen every company in Pharmaceutical Preparations ↗